PER-036-13Unknown未知
Phase III clinical trial, double-blind, randomized, controlled with methyl salicylate 30 g to evaluate the safety and effectiveness of methyl salicylate 30 g and 1 g benzocaine ointment as an adjunct in the treatment of knee osteoarthritis and musculoskeletal pain.
ABORATORIOS FARMASUR S.A.C.,0 sites0 target enrollmentStarted: April 30, 2014Last updated:
Trial Snapshot
- Phase
- 未知
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 90 (—)
- Sex
- All
Inclusion Criteria
- •Patients over 18 years
- •oWith clinical diagnosis (contained in medical records) of:
- •Knee pain and osteoarthritis product
- •musculoskeletal pain or mechanical type (low back pain, neck pain, knee pain)
- •They have given their informed consent.
Exclusion Criteria
- •Be excluded:
- •Patients with any history of adverse reactions of components forming part of the treatment.
- •Patients with lesions / wounds or conditions that impair the integrity of the skin in the areas where the product is applied.
- •Women pregnant or breastfeeding are providing.
Investigators
Similar Trials
Unknown
Phase 3
Phase 3,randomized,double-blind,clinical trial of IKH-01 for treatment of dysmenorrhea associated with endometriosis.dysmenorrhea associated with endometriosis.JPRN-jRCT2080220111obelpharma Co., Ltd.
Active, not recruiting
Phase 1
Clinical trial to evaluate ascorbic acid (vitamin C) and tocopherol (vitamin E) in combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndromeFragile x syndromeMedDRA version: 19.0Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-005460-42-ESFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Active, not recruiting
Phase 1
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaHER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-001757-27-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,542
Active, not recruiting
Phase 1
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaHER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaMedDRA version: 27.0Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001757-27-IEMerck Sharp & Dohme LLC1,542
Active, not recruiting
Phase 1
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaEUCTR2018-001757-27-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.1,542